A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/20/2011	US20110256114 T-cell receptor and nucleic acid encoding the receptor
10/20/2011	US20110256104 Complexing agents for compositions containing inclusion complexes
10/20/2011	US20110256103 method of producing a pharmacologically stable form of lyophilised, active preparations of purified bacteriophages
10/20/2011	US20110256093 Treating Disorders Associated with IL-20 Receptor-Mediated Signaling Pathway by Blocking IL-20 Receptor Activity
10/20/2011	US20110256092 Quinoline derivatives for modulating dna methylation
10/20/2011	US20110256091 Antibody-Targeted Cytokines for Therapy
10/20/2011	US20110256090 Method for Identifying Genes Involved in Trail-Induced Apoptosis and Therapeutic Applications Thereof
10/20/2011	US20110256066 Method for preparing engineered mg doped ferrite superparamagnetic nano particle exhibiting ac magnetic induction heating at high temperature and mg doped ferrite superparamagnetic nano particles engineered by the method
10/20/2011	US20110256064 Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-like Proteins
10/20/2011	US20110256060 Monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therpay
10/20/2011	US20110256058 Novel Peptides and Uses Thereof
10/20/2011	US20110256057 Cyclic Azapeptides as Integrin Markers and Methods of Using
10/20/2011	US20110256056 Monoclonal Antibodies Against HER2 Antigens, and Uses Therefor
10/20/2011	US20110256053 Multiple Signaling Pathways Induced by Hexavalent, Monospecific and Bispecific Antibodies for Enhanced Toxicity to B-Cell Lymphomas and Other Diseases
10/20/2011	CA2800327A1 Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
10/20/2011	CA2796419A1 Compositions and methods for the prevention and treatment of cancer
10/20/2011	CA2796205A1 Combination treatment with vegf-c antagonists
10/20/2011	CA2796070A1 Androgen induced oxidative stress inhibitors
10/20/2011	CA2796064A1 Treating disorders associated with il-20 receptor-mediated signaling pathway by blocking il-20 receptor activity
10/20/2011	CA2796063A1 Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
10/20/2011	CA2796053A1 Methods and compositions for inhibition of treg cells
10/20/2011	CA2796010A1 Trail r2-specific multimeric scaffolds
10/20/2011	CA2796008A1 Inhibitors of protein tyrosine kinase activity
10/20/2011	CA2795952A1 Treatment of cancers having k-ras mutations
10/20/2011	CA2795947A1 Method for treating solid tumors
10/20/2011	CA2795360A1 Tissue targeting
10/20/2011	CA2795353A1 Pyrrolobenzodiazepines used to treat proliferative diseases
10/20/2011	CA2795349A1 Targeted pyrrolobenzodiazepine conjugates
10/20/2011	CA2795089A1 Combination of organic compounds
10/20/2011	CA2794863A1 Anti-vla-4 antibodies
10/20/2011	CA2794861A1 Pyrrolopyrazinone inhibitors of kinases
10/20/2011	CA2794859A1 Phthalazin-(2h)-one inhibitors of kinases
10/20/2011	CA2794406A1 Triazole compounds as ksp inhibitors
10/20/2011	CA2793890A1 Pyrrolobenzodiazepines and conjugates thereof
10/20/2011	CA2793779A1 Organic compound for use in the treatment of liver cancer
10/19/2011	EP2377932A1 ANTI-Siglec-15 ANTIBODY
10/19/2011	EP2377891A1 Diagnosis and treatment of cancer using anti-lgr7 antibody
10/19/2011	EP2377875A1 Antioxidant
10/19/2011	EP2377871A1 1-(2h)-isoquinolone derivative
10/19/2011	EP2377849A2 Chemical inhibitor of p53-snail binding and pharmaceutical composition for treating cancer disease containing same as its active ingredient
10/19/2011	EP2377559A1 Targeting cells with altered microRNA expression
10/19/2011	EP2377548A2 Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
10/19/2011	EP2377532A1 Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists for treating dermatological disorders
10/19/2011	EP2376537A2 Human antibodies against human tissue factor.
10/19/2011	EP2376535A1 Anti-pd-l1 antibodies and their use to enhance t-cell function
10/19/2011	EP2376500A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene maleate salt
10/19/2011	EP2376499A1 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
10/19/2011	EP2376498A1 Novel c-1analogs of pancratistatin and 7-deoxypancratistatin and processes for their preparation
10/19/2011	EP2376494A1 Dihydropyrimidopyrimidine derivatives
10/19/2011	EP2376493A1 Dihydropyrimidopyrimidine derivative
10/19/2011	EP2376492A1 3,4 DIHYDRO-2H-PYRROLO[1,2-a]PYRAZIN-1-ONE DERIVATIVES
10/19/2011	EP2376491A1 Pyrrolotriazines as alk and jak2 inhibitors
10/19/2011	EP2376485A1 Pyrazine derivatives useful as inhibitors of atr kinase
10/19/2011	EP2376481A1 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
10/19/2011	EP2376480A2 Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
10/19/2011	EP2376478A2 Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
10/19/2011	EP2376462A1 Thiazoles as cannabinoid receptor ligands
10/19/2011	EP2376425A2 Kinase inhibitor compounds
10/19/2011	EP2376197A2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
10/19/2011	EP2376122A2 Agent for prophylaxis or treatment of cancer
10/19/2011	EP2376116A2 Anti-igf antibodies
10/19/2011	EP2376105A1 Nkg2d-fc for immunotherapy
10/19/2011	EP2376089A1 Cancer vaccine compositions and methods of using the same
10/19/2011	EP2376084A1 Cdk inhibitor for the treatment of mesothelioma
10/19/2011	EP2376081A2 Enzastaurin for the treatment of cancer
10/19/2011	EP2376076A1 Antitumor combination combining ave8062 and docetaxel
10/19/2011	EP2375897A1 Methods and compositions containing mtor inhibitors for enhancing immune responses
10/19/2011	EP2225245B1 N-phenyl-imidazo(1,2-a)pyridine-2-carboxamide compounds, preparation thereof and therapeutic application thereof
10/19/2011	EP2221377B1 Oligonucleotide compositions with enhanced efficiency
10/19/2011	EP1930346B1 Antibody produced using ostrich and method for production thereof
10/19/2011	EP1917012B1 Cell migration modulating compounds
10/19/2011	EP1736206B1 Physiologically active composition and process for producing the same
10/19/2011	EP1640371B1 Flavanone compound and uses thereof
10/19/2011	EP1563308B1 Methods and kits for diagnosing tumorigenicity
10/19/2011	EP1513506B1 Targeting system comprising uniformly-sized nanoparticles with at least one polymer and at least one positively-charged polysaccharide and preparation method thereof
10/19/2011	EP1499613B1 Thioxanthine derivatives as myeloperoxidase inhibitors
10/19/2011	EP1482931B1 Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
10/19/2011	EP1383793B1 Insulin and igf-1 receptor agonists and antagonists
10/19/2011	EP1372735B1 Conjugate of hydroxyalkyl starch and an active agent
10/19/2011	EP1282615B1 Chroman derivatives as estrogenic compounds
10/19/2011	EP1165132B1 Dry formulation for transcutaneous immunization
10/19/2011	EP1041982B1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
10/19/2011	CN202011849U Equipment for extracting and concentrating polysaccharide from medicinal materials
10/19/2011	CN1980671B Liposome preparation containing slightly water-soluble camptothecin
10/19/2011	CN1251097B Phthalazines with angiogenesis inhibiting activity
10/19/2011	CN102224170A Materials and methods for inhibiting cancer cell invasion related to fgfr4
10/19/2011	CN102224152A Pyrazolopyridine pi3k inhibitor compounds and methods of use
10/19/2011	CN102224144A Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine
10/19/2011	CN102224138A Indole derivatives, method for preparing same and pharmaceutical compositions containing same
10/19/2011	CN102223915A New therapy and medicament using integrin ligands for treating cancer
10/19/2011	CN102223897A Anti-angiogenesis therapy for the treatment of breast cancer
10/19/2011	CN102223896A Anti-beta-2-microglobulin agents and the use thereof
10/19/2011	CN102223885A Cdk inhibitor for the treatment of mesothelioma
10/19/2011	CN102220423A Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
10/19/2011	CN102220336A Tumour chemotherapy drug sensitive gene and application of same
10/19/2011	CN102220335A Guanine-rich nucleic acid aptamer and application thereof
10/19/2011	CN102220283A Multifunctional immune killing transgenic cell as well as preparation method and use thereof
10/19/2011	CN102220255A Recombinant antimicrobial peptide (AMP) as well as genetic engineering preparation method and application thereof
10/19/2011	CN102219865A Preparation method of cherokee rose polysaccharide derivatives with antitumor activity
10/19/2011	CN102219860A FGFR-Fc fusion protein and applications thereof

1 ... 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 ... 2211